Molecular Formula | C17H12F3NO4S
|
Molar Mass | 383.34 |
Density | 1.57±0.1 g/cm3(Predicted) |
Boling Point | 524.7±50.0 °C(Predicted) |
Solubility | 10 mM in DMSO |
pKa | 11.28±0.40(Predicted) |
Storage Condition | Sealed in dry,Store in freezer, under -20°C |
In vitro study | PT2385 prevents the dimerization of HIF-2α with ARNT/HIF1β. In ccRCC cell lines and xenograft models, PT2385 inhibition is dependent on HIF2α gene expression, including VEGF-A, PAI-1, and cyclin D1. At a concentration of 10 μm, PT2385 had no effect on the proliferation and viability of 786-O and A498 cells. Treatment of 786-O cells with PT2385 significantly reduced the levels of CCND1, VEGF-A, GLUT1 and PAI-1 mRNA. Treatment of Hep3B cells with PT2385 reduced hypoxia-induced erythropoietin and PAI-1 expression. |
In vivo study | PT2385 has high oral bioavailability (110%) with low-moderate in vivo clearance in mice. The half-life of PT2385 was 3.3 h by intravenous administration to mice. A pharmacokinetic study was carried out in rats and the oral bioavailability of 10 mg/kg PT2385 was 40% with a half-life of 3.3 hours. In dogs, PT2385 has an oral bioavailability of 87% and a half-life of 11 hours. Treatment of tumor-bearing mice (clear cell renal cell carcinoma) with PT2385 resulted in significant tumor regression. PT2385 had no adverse effects on cardiovascular function. |